A new study published in Nutrients this month asked an unusual question about oleocanthal – one of olive oil's most-studied phenolic compounds. Oleocanthal was already known to suppress colorectal tumors, and already known to reshape gut bacteria. But, are the two connected?
The short version
Researchers gave tumor-bearing mice purified oleocanthal by mouth and saw primary tumor burden fall by 97–99%. Then they took gut bacteria from healthy mice that had been given oleocanthal, transferred those bacteria into tumor-bearing mice that received no oleocanthal at all, and saw tumor burden fall by more than 99%. The anti-tumor effect traveled with the microbiome.
One thing to be clear about from the outset, because it shapes how every number below should be read: the mice received purified oleocanthal delivered by oral gavage, not olive oil. The compound was isolated from The Governor extra virgin olive oil – an oil kyoord distributes exclusively in the United States – but the experiment tested the isolated phenolic at pharmaceutical purity, not the oil itself. This is preclinical animal research. It does not establish that any olive oil prevents, treats, or cures disease in people.
With that said, it is a genuinely interesting piece of work, and worth understanding properly.
A Study Built to Test the Gut, Not Just the Tumor
This paper is a direct follow-up to research the same lab published in January 2025. That earlier study identified oleocanthal as the most active anti-colorectal-cancer compound among the olive phenolics they screened, and showed it suppressing tumor growth and post-surgical recurrence through three targets: SMYD2, EZH2, and c-MET.
But that work used a subcutaneous xenograft model, which involves tumors implanted under the skin. This tactic is useful for asking whether a compound has activity at all, but less useful for colorectal cancer specifically, because a tumor under the skin sits nowhere near the intestine.
So this time the researchers implanted the tumors where colorectal cancer actually grows. About 5 million human HCT-116-Luc colorectal cancer cells, carrying the KRAS G13D mutation, were injected directly into the wall of each mouse's cecum. The cells were engineered to emit light, so tumor growth and spread could be tracked by bioluminescence imaging rather than only measured at the end.
How the Study Was Designed
Male and female athymic nude mice were orthotopically implanted, then randomized into four groups once tumors were established. Oral treatments were given daily, while injected oleocanthal was given three times per week:
- Oral oleocanthal – 10 mg/kg per day
- Oral oleocanthal + antibiotics – the same dose, with the gut microbiome depleted
- Injected oleocanthal – 10 mg/kg intraperitoneally, three times per week
- Placebo control – de-phenolized extra virgin olive oil, plus a broad-spectrum antibiotic cocktail (de-phenolized meaning olive oil that was stripped of all polyphenols)
Two design details deserve attention.
First, the placebo was de-phenolized extra virgin olive oil, which is a meaningfully better control than a saline placebo, because it means the comparison isolates the phenolics rather than comparing olive oil against nothing.
Second, the study ran both sexes in parallel throughout, which is still not universal in preclinical work and makes the consistency of the results more informative.
The oleocanthal itself was isolated from The Governor extra virgin olive oil.
Key Findings
Total primary tumor weight after 21 days:
| Group | Male | Female |
|---|---|---|
| Dephenolized EVOO + antibiotics (control) | 7,404.5 mg | 6,540.1 mg |
| Oral oleocanthal, 10 mg/kg/day | 178.4 mg | 62.6 mg |
| Oral oleocanthal + antibiotics | 212.8 mg | 262.6 mg |
| Injected oleocanthal, 3×/week | 2,617.7 mg | 1,968.0 mg |
That works out to a 97.6% reduction in males and roughly 99% in females for daily oral oleocanthal.
On metastasis, the researchers examined eight organs by bioluminescence: liver, intestine, spleen, kidney, bone, brain, lung, and heart.
- Control mice showed metastases in the liver, intestine, spleen, and kidney of every animal, with additional spread to bone, brain, and lung in some.
- In females on oral oleocanthal, no metastases were detected in the liver, spleen, kidney, bone, brain, lung, or heart. Intestinal involvement remained in 5 of 6.
- In males on oral oleocanthal, spleen, bone, brain, lung, and heart metastases were completely prevented; liver involvement dropped to 2 of 6, and intestinal involvement remained in 5 of 6.
Loss of body weight is another hallmark of cancer progression, and the control mice lost weight steadily as disease advanced. Mice on oral oleocanthal held steady.
Oral vs. Injected Oleocanthal
Injected oleocanthal bypasses the intestine, so it does not interact directly with the gut microbiome before entering circulation. If oleocanthal’s effects were driven mainly by direct action on the tumor, you might expect injection to work at least as well as oral dosing.
Instead, the oral treatment produced a much greater reduction in tumor burden. Injected oleocanthal reduced tumor weight by 64.6% in males and 69.9% in females, compared with 97.6% and about 99%, respectively, with oral dosing.
The comparison is not perfect because the oral group received a higher total dose over the course of the week, but the difference was large enough to raise the possibility that something happening in the intestine was contributing to the effect.
Because the oral and injected groups did not receive the same total weekly dose, this comparison cannot cleanly separate the effect of route from the effect of cumulative dose. Still, when considered alongside the antibiotic and fecal transplant experiments, it suggests that the intestinal environment may be contributing to oleocanthal’s activity.
To explore that possibility, the researchers treated mice with a broad-spectrum antibiotic cocktail to substantially deplete the gut microbiome, then gave them oral oleocanthal. If the microbiome accounted for most of the effect, you would expect tumor suppression to fall sharply.
However, it did not. Tumor burden was still reduced by 97.1% in males and 96.0% in females. That suggests oleocanthal has strong anti-tumor activity even when the gut microbiome is substantially reduced.
There were, however, some differences. Tumor suppression was slightly weaker than with oral oleocanthal alone, and the effect on metastasis was less complete, particularly in females, where liver metastases were detected in 4 of 6 mice. The study didn't verify how completely the antibiotics depleted the microbiome, so this experiment can't tell us exactly how much of the effect depends on it.
That led to the next experiment: transferring fecal material from oleocanthal-treated mice into tumor-bearing mice.
What Happened When the Microbiome Was Transferred
The researchers took healthy donor mice – no tumors – and gave them either de-phenolized olive oil or a higher dose of oral oleocanthal, 20 mg/kg daily. Fresh fecal material was collected from these donors every day.
Separately, tumor-bearing recipient mice had their own gut microbiome depleted with antibiotics for a week. Then they received daily fecal microbiota transplants from one donor group or the other, for 21 days.
The recipients never received oleocanthal.
Total primary tumor weight:
| Group | Male | Female |
|---|---|---|
| FMT from control donors | 9,252.2 mg | 6,594.8 mg |
| FMT from oleocanthal-treated donors | 48.5 mg | 38.4 mg |
| Oral oleocanthal (reference arm) | 211.2 mg | 186.8 mg |
That is a 99.5% reduction in males and 99.4% in females – and in this experiment, the transplanted microbiome outperformed the oleocanthal itself.
Metastasis was also markedly reduced. Among male mice receiving FMT from oleocanthal-treated donors, only one metastatic lesion was detected, in the kidney of 1 of 6 animals. No metastases were detected in the other seven organs examined. In females, metastases were limited to one intestinal lesion and one spleen lesion. By comparison, the control FMT groups showed widespread metastatic involvement, particularly in the liver, intestine, spleen, and kidney.
SMYD2 and EZH2: Oleocanthal’s Impact
SMYD2 and EZH2 are epigenetic regulators – enzymes that alter how genes are read rather than changing the genes themselves. Both are overexpressed in invasive and metastatic colorectal cancer, and the 2025 study had already identified them as oleocanthal targets.
Oral oleocanthal suppressed both here, reproducing that earlier finding in the harder model: SMYD2 down roughly 65% in males and 71% in females, EZH2 down roughly 88% and 86%.
The interesting part is that the fecal transplant did nearly the same thing. In recipients who never received oleocanthal, SMYD2 fell 60–62% in males and about 68% in females; EZH2 fell about 83% and 76%.
That FMT from oleocanthal-treated donors was associated with suppression of the same two tumor-associated proteins is particularly intriguing.
What the Dose Would Mean in Human Terms
The authors also estimated what the mouse dose would correspond to in humans. Using the standard 0.081 mouse-to-human body-surface-area conversion factor, the 10 mg/kg mouse dose translates to approximately 0.81 mg/kg in humans, or about 56.7 mg of oleocanthal per day for a 70 kg (154 lbs) adult. They note that an extra virgin olive oil containing around 1,000 mg of oleocanthal per liter would provide that amount in roughly 57 mL of oil, which they describe as a realistic dietary quantity.
That calculation needs some context. It is a human-equivalent dose estimate, not an established human dose. Body-surface-area scaling is commonly used as a starting point when translating animal research, but it does not tell us what dose would be effective in people. Human pharmacokinetic data for oleocanthal are currently unavailable, so we do not yet know how its absorption, metabolism, or systemic exposure compares between mice and humans. The authors themselves describe the translational relevance of this calculation as preliminary.
There is another important difference: the mice received purified oleocanthal by oral gavage, not olive oil as part of a meal. In food, oleocanthal is consumed within a complex mixture of fats and other phenolic compounds, which may affect its absorption and biological activity.
Dose and duration also matter when considering safety. The paper cites a separate study in which single oral doses as high as 500 mg/kg caused no mortality in mice, while prolonged dosing at 20 mg/kg for four months was associated with liver toxicity. That does not mean the 20 mg/kg dose used in the fecal donor mice in this study was toxic, since the treatment period was much shorter, but it is a useful reminder that animal doses cannot simply be extrapolated into a recommendation for human use.
One technical distinction is also worth making. The 1,000 mg/L figure in the paper refers specifically to oleocanthal, not total polyphenols. kyoord currently offers oils with approximately 375 to 1,260 mg/kg of oleocanthal, while The Governor itself contains about 500 mg/kg. These values are measured separately from total polyphenol content and are third-party verified.
Featured Olive Oil
The Governor, Premium Edition
Researchers took The Governor olive oil and purified oleocanthal to 99%.
Shop the Premium EditionLimitations Worth Noting
The study also has some important limitations.
The mice were athymic nude mice, meaning they have a severely impaired adaptive immune system. That is especially relevant in a study focused on the gut microbiome, since immune signaling is one of the major ways gut microbes can influence cancer biology. The effects seen here therefore occurred in a model that does not fully reproduce the immune response you would expect in humans.
The researchers also used a single colorectal cancer cell line, HCT-116, carrying the KRAS G13D mutation. These results cannot be assumed to apply to other KRAS mutations, all colorectal cancers, or other cancer types.
The study did not identify which changes in the microbiome were responsible for the effect. There was no 16S sequencing, metagenomic analysis, or metabolomic profiling, so we do not yet know which bacteria or metabolites may have been involved.
It is also important to remember that the fecal transplants contained more than bacteria. Fresh fecal material also contains microbial metabolites and potentially oleocanthal-derived metabolites. The experiment shows that the effect could be transferred through fecal material, but it does not establish exactly what component was responsible.
These limitations do not diminish the significance of the findings, but they do define what the study can and cannot tell us. At this stage, the results provide a strong rationale for further research, not evidence that oleocanthal is a treatment for colorectal cancer.
What You Need to Know
For years, research on olive phenolics has asked what these compounds do to our cells. This study is part of a growing body of work asking a different question: what happens when olive phenolics meet the hundred trillion organisms already living in our gut, and what do those interactions produce?
That reframing has a practical edge. If part of what makes oleocanthal interesting depends on it reaching the intestine intact, then how you consume high-phenolic olive oil starts to matter as much as how much you consume:
What you need to know
- —Look for verified oleocanthal numbers, not just total polyphenols. Most brands publish neither. Oleocanthal is the compound in this research, and it's measured separately.
- —Concentration matters, not just volume. A 2025 clinical trial found a small dose of high-phenolic olive oil outperformed a larger dose of moderate-phenolic oil at the same total polyphenol intake. See what that trial found →
- —Store it properly. Light, heat, and oxygen degrade the compounds you're paying for. Olive oil storage guide →
- —Be consistent. Phenolics don't accumulate the way fat-soluble vitamins do. Regular intake is what the research consistently rests on.
The oleocanthal used in this work was naturally isolated from The Governor Premium Extra Virgin Olive Oil. That does not mean the study tested The Governor as a cancer intervention. It means an exceptionally oleocanthal-rich olive oil served as the natural source of the purified compound studied.
Frequently Asked Questions
What is oleocanthal?
Oleocanthal is a phenolic compound found in extra virgin olive oil, and one of the main sources of the peppery, throat-catching sensation some high-phenolic oils produce. It is measured separately from total polyphenol content.
How is oleocanthal different from oleacein?
Both are secoiridoid-related phenolics found in virgin olive oils, and both are studied for anti-inflammatory activity, but they are distinct compounds with distinct research literatures. An oil high in one is not necessarily high in the other, which is why they're reported separately on lab analyses.
Can I tell how much oleocanthal an olive oil contains by how peppery it is?
Yes, but unreliably. Pungency is a useful clue that phenolics are present, but it can't quantify them, and it can't tell you which phenolics. A strongly peppery oil isn't automatically high in oleocanthal specifically. Laboratory analysis is the only way to know.
Did this study test The Governor olive oil?
No. Researchers used The Governor extra virgin olive oil as the source material from which they extracted and purified oleocanthal to at least 99% purity. The mice received the isolated compound, not the oil.
Does cooking destroy oleocanthal?
Heat degrades phenolic compounds, and oleocanthal is no exception. This is why high-phenolic oils are generally best used raw or added at the end of cooking when the compounds are what you're after.
What kind of colorectal cancer did the study look at?
Human HCT-116 colorectal cancer cells carrying a KRAS G13D mutation, implanted into the cecal wall so tumors would develop inside the intestinal environment rather than under the skin.
Why does the fecal transplant result matter?
Because it separates two possible explanations. If oleocanthal only acted directly on tumor cells, transferring gut bacteria from treated animals to untreated animals should do nothing. It did a great deal – which suggests the intestinal environment is part of the mechanism rather than a bystander.
Does this identify a beneficial bacterium that fights colorectal cancer?
No. The study didn't sequence the microbiome or profile metabolites, so no organism, compound, or pathway has been identified. That work remains to be done.
Does this mean high-phenolic olive oil can treat colorectal cancer?
No. This was an animal study using a purified compound at pharmaceutical purity, in mice with an impaired immune system, against a single cell line. It does not show that olive oil prevents, treats, or cures colorectal cancer in humans. What it shows is that oleocanthal warrants continued investigation, including human clinical trials.
Statements on this site have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Reference: Tarun, M. T. I., Ebrahim, H. Y., & El Sayed, K. A. (2026). Lead Validation of the Olive Phenolic S-(−)-Oleocanthal for Effective Control of KRAS^G13D^-Mutant Colorectal Cancer Progression and Metastasis. Nutrients, 18(16), 2623. https://doi.org/10.3390/nu18162623
Prior study referenced: Tarun, M. T. I., Elsayed, H. E., Ebrahim, H. Y., & El Sayed, K. A. (2025). The Olive Oil Phenolic S-(−)-Oleocanthal Suppresses Colorectal Cancer Progression and Recurrence by Modulating SMYD2-EZH2 and c-MET Activation. Nutrients, 17(3), 397. https://doi.org/10.3390/nu17030397
